MARIE-CLAIRE PEAKMAN, MRPHARMS, PHD is Executive Director, WRDM and Partner at Pfizer Ventures. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in DEM Biopharma, Grey Wolf Therapeutics and Mozart Therapeutics and holds observer positions on the boards of Mediar Therapeutics, Capstan Therapeutics, TRex Bio and Crossbow Therapeutics.

Marie-Claire brings 25 years of scientific leadership at Pfizer, delivering small molecule therapeutics to the clinic and to market across multiple therapeutic areas. Most recently she led the Primary Pharmacology Group which she founded in 2009 and which played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. She has additional experience leading compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She has multiple roles on non-profit boards in the community.

Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.

Email: [email protected]